Major Depressive Disorder Studies
Major Depressive Disorder
Phase 2-4Active
Key Facts
About Noesis Pharma Clinical Trials
NoesisPharma is a private, physician-owned clinical research site founded in 2010 (with operational data suggesting 2015) and based in Phoenix, Arizona. The company provides clinical trial services for Phase II-IV studies, with a core therapeutic focus on psychiatry and CNS disorders. Led by its founder and Medical Director, Dr. Lee Ann Kelley, the organization leverages a team with decades of combined clinical and research experience to conduct trials for external biopharma sponsors, operating under a fee-for-service business model.
View full company profileTherapeutic Areas
Other Major Depressive Disorder Drugs
| Drug | Company | Phase |
|---|---|---|
| Accelerated Deep TMS Protocol | BrainsWay | FDA Cleared |
| ZURZUVAE (zuranolone) | Sage Therapeutics | Phase 3 |
| MDD Clinical Trials | Boston Clinical Trials | Not Specified (Typically Phase 2-3) |
| NMDAR Antagonist (GM-2505/Bretisilocin) | Gilgamesh Pharmaceuticals | Phase 2 |
| Neuroplastogen (GM-1020) | Gilgamesh Pharmaceuticals | Phase 2a |
| NA-901 | Biomed | Phase 2B/3 |
| SP-624 (Forvisirvat) | Arrivo BioVentures | Phase 2 |
| NBS System for MDD | Nexstim | Approved |
| Depression Studies | Pacific Clinical Research Medical Group | Phase 2/3 |
| Neurotyping Platform for MDD | Universal Brain | Development |
| CLE-100 | Clexio Biosciences | Phase 2 |
| Proliv™Rx | Neurolief | Phase 2 |